A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults | Scientific Reports
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults | Scientific Reports,A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults | Scientific Reports,2025シーズンユニフォーム」店頭販売のお知らせ | KAWASAKI FRONTALE,StopCOVID19 Japan 新型コロナウイルス対策ダッシュボードの更新終了と、NIID感染症オープンデータの収集開始のお知らせ,Biomed Industries.™ News- Press Release-Biomed announced its Phase 1B clinial results of NA-831 for the treatment of Major Depressive Disorder.